comparemela.com

InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease

InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Auckland ,New Zealand ,Davids Boyer ,Philipj Rosenfeld ,Retina Network ,National Eye Institute ,Vitreous Associates Medical Group ,Inflammx Therapeutics Inc ,Drug Administration ,Bascom Palmer Eye Institute ,University Of Auckland ,Wall Street ,Diabetic Macular Edema ,Diabetic Nephropathy ,National Eye ,Related Macular Degeneration ,Geographic Atrophy ,Investigational New Drug ,Aged Related Macular Degeneration ,Brian Levy ,Chief Executive Officer ,Board Member ,Retina Vitreous Associates Medical Group ,Inflammx Therapeutics ,David Pool ,

comparemela.com © 2020. All Rights Reserved.